US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocera Therapeutics

1.79

0.0000

Volume:- -

Turnover:- -

Market Cap:47.45M

PE:-1.70

High:1.79

Open:1.79

Low:1.79

Close:1.79

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Ocera Therapeutics

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.ocerainc.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OCRX/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCRX\",,,,,undefined,":{"symbol":"OCRX","market":"US","secType":"STK","nameCN":"Ocera Therapeutics","latestPrice":1.79,"timestamp":1512766800000,"preClose":1.79,"halted":3,"volume":0,"delay":0,"floatShares":10646000,"shares":26510000,"eps":-1.05,"marketStatus":"Halted","change":0,"latestTime":"05-21 07:53:57 EDT","open":1.79,"high":1.79,"low":1.79,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.05,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747834200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1301889600000,"exchange":"NASDAQ","adjPreClose":1.79,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCRX\",,,,,undefined,":{"symbol":"OCRX","floatShares":10646000,"roa":"--","roe":"--","lyrEps":0,"shares":26510000,"dividePrice":0,"high":1.79,"amplitude":0,"preClose":1.79,"low":1.79,"week52Low":0.52,"pbRate":"5.12","week52High":2.95,"institutionHeld":0,"latestPrice":1.79,"eps":-1.05,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.05,"open":1.79,"prevYearClose":1.79},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ocerainc.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":0.1262},{"period":"3month","weight":-0.0328},{"period":"6month","weight":-0.0014},{"period":"1year","weight":0.1185},{"period":"ytd","weight":0.0116}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.","exchange":"NASDAQ","name":"Ocera Therapeutics","nameEN":"Ocera Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OCRX\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-14","symbol":"OCRX","fiscalQuarterEnding":"2017/09","expectedEps":-0.24,"name":null,"time":"","type":"earning","dateTimestamp":1510635600000,"reportTimeType":"","actualEps":-0.24},{"market":"US","date":"2017-08-01","symbol":"OCRX","fiscalQuarterEnding":"2017/06","expectedEps":-0.23,"name":null,"time":"","type":"earning","dateTimestamp":1501560000000,"reportTimeType":"","actualEps":-0.23},{"market":"US","date":"2017-05-09","symbol":"OCRX","fiscalQuarterEnding":"2017/03","expectedEps":-0.24,"name":null,"time":"","type":"earning","dateTimestamp":1494302400000,"reportTimeType":"","actualEps":-0.28},{"market":"US","date":"2017-03-10","symbol":"OCRX","fiscalQuarterEnding":"2016/12","expectedEps":-0.34,"name":null,"time":"","type":"earning","dateTimestamp":1489122000000,"reportTimeType":"","actualEps":-0.22},{"market":"US","date":"2016-11-02","symbol":"OCRX","fiscalQuarterEnding":"2016/09","expectedEps":-0.36,"name":null,"time":"","type":"earning","dateTimestamp":1478059200000,"reportTimeType":"","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OCRX\",market:\"US\",delay:false,,,undefined,":{}}}